Search
Now showing items 1-10 of 25
Pembrolizumab given concomitantly with chemoradiation and as maintenance therapy for locally advanced head and neck squamous cell carcinoma: KEYNOTE-412.
(FUTURE MEDICINE LTD, 2020-06-03)
Current treatment guidelines for patients with locally advanced head and neck squamous cell carcinoma (HNSCC) recommend multimodal treatment, including chemoradiation therapy (CRT) or surgery followed by radiation, with ...
Comparing programmed death ligand 1 scores for predicting pembrolizumab efficacy in head and neck cancer.
(ELSEVIER SCIENCE INC, 2020-11-25)
Tumor proportion score (TPS) and combined positive score ([CPS] includes immune cells), 2 methods for scoring programmed death ligand 1 (PD-L1) expression, have been used in clinical trials investigating the immune checkpoint ...
Impact of antibiotic use during curative treatment of locally advanced head and neck cancers with chemotherapy and radiotherapy.
(ELSEVIER SCI LTD, 2020-05-01)
BACKGROUND: Pre-clinical evidence suggests reduced efficacy of anticancer treatment in patients exposed to broad-spectrum antibiotics. It is hypothesised that this phenomenon may be explained by the effects of antibiotics ...
Prostate-specific membrane antigen expression in melanoma metastases.
(WILEY, 2020-12-01)
BACKGROUND: Prostate-specific membrane antigen (PSMA) is a prostatic epithelial protein that is used as a radiotracer (68Ga-PSMA-11) for prostate cancer staging. PSMA-PET/CT (positron emission tomography/computed tomography) ...
Current challenges for assessing the long-term clinical benefit of cancer immunotherapy: a multi-stakeholder perspective.
(BMJ PUBLISHING GROUP, 2020-01-01)
Immuno-oncologics (IOs) differ from chemotherapies as they prime the patient's immune system to attack the tumor, rather than directly destroying cancer cells. The IO mechanism of action leads to durable responses and ...
Consensus guidelines for the definition, detection and interpretation of immunogenic cell death.
(BMJ PUBLISHING GROUP, 2020-01-01)
Cells succumbing to stress via regulated cell death (RCD) can initiate an adaptive immune response associated with immunological memory, provided they display sufficient antigenicity and adjuvanticity. Moreover, multiple ...
Changing paradigms in the treatment of residual/recurrent head and neck cancer: implications for dysphagia management.
(LIPPINCOTT WILLIAMS & WILKINS, 2020-06-01)
PURPOSE OF REVIEW: Despite advances in head and neck cancer treatment provision, recurrence rates remain high with the added risk of successfully treated patients developing a second primary. We report on the management ...
Cost-effectiveness analysis of nivolumab for the treatment of squamous cell carcinoma of the head and neck in the United States.
(TAYLOR & FRANCIS LTD, 2020-05-03)
Aim: To assess the cost-effectiveness of nivolumab monotherapy for recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) in the US.Methods: We constructed a cohort-based partitioned survival model ...
The PERK Inhibitor GSK2606414 Enhances Reovirus Infection in Head and Neck Squamous Cell Carcinoma via an ATF4-Dependent Mechanism.
(CELL PRESS, 2020-03-27)
Reovirus type 3 Dearing (reovirus) is a tumor-selective oncolytic virus currently under evaluation in clinical trials. Here, we report that the therapeutic efficacy of reovirus in head and neck squamous cell cancer can be ...
Combination therapy with oncolytic viruses and immune checkpoint inhibitors.
(TAYLOR & FRANCIS LTD, 2020-06-02)
Introduction: Immune checkpoint inhibitors (ICI) have dramatically improved the outcome for cancer patients across multiple tumor types. However the response rates to ICI monotherapy remain relatively low, in part due to ...